Sand Hill Global Advisors’s Corcept Therapeutics CORT Stock Holding History

Sand Hill Global Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$157K	–	102
2018 Q2	$157K	Hold	10,000	–	–	0.02%	103
2018 Q1	$165K	Hold	10,000	–	–	0.16%	77
2017 Q4	$181K	Hold	10,000	–	–	0.02%	110
2017 Q3	$193K	Hold	10,000	–	–	0.02%	111
2017 Q2	$118K	Buy	+10,000	New	+$109K	0.01%	107

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sand Hill Global Advisors's CORT Position: Q3 2018 in Review

Sand Hill Global Advisors sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 10,000 shares — an estimated $157K sold.

Sand Hill Global Advisors first reported a position in CORT in Q2 2017 and held it in 5 quarters. The position peaked at $193K in Q3 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

Sand Hill Global Advisors reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
Sand Hill Global Advisors sold 10,000 Corcept Therapeutics shares in Q3 2018, an estimated $157K.
Sand Hill Global Advisors first reported a position in Corcept Therapeutics in Q2 2017 and held it in 5 quarters.
Sand Hill Global Advisors's Corcept Therapeutics position peaked at $193K in Q3 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Sand Hill Global Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.